• OPEN AN ACCOUNT
Indian Indices
Nifty
17,757.00 -181.40
(-1.01%)
Sensex
59,464.62 -634.20
( -1.06%)
Bank Nifty
37,850.85 -190.50
( -0.50%)
Nifty IT
36,662.20 -619.50
( -1.66%)
Global Indices
Nasdaq
14,340.26 -166.64
(-1.15%)
Dow Jones
35,028.65 -339.82
(-0.96%)
Hang Seng
24,952.35 824.50
(3.42%)
Nikkei 225
27,772.93 305.70
(1.11%)
Forex
USD-INR
74.40 0.00
(0.00%)
EUR-INR
84.35 -0.25
(-0.29%)
GBP-INR
101.29 0.00
(0.00%)
JPY-INR
0.65 0.00
(0.21%)

EQUITY - MARKET SCREENER

Home First Finance Company India Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
543259
INE481N01025
167.0000103
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
HOMEFIRST
56.07
7130.88
EPS(TTM)
Face Value()
Div & Yield %
14.52
2
0
 

sun pharmaceuticals industries ltd
Sun Pharma receives USFDA approval for generic Amphotericin B Liposome for Injection
Dec 15,2021
Sun Pharmaceuticals Industries announced that one of its wholly-owned subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial. The generic product approval is based on AmBisome® Liposome for Injection, 50 mg/vial as a reference product.

Sun Pharma has been granted Competitive Generic Therapy (CGT) designation by US FDA and being the first approved generic, is eligible for 180 days of CGT exclusivity for the product.

As per October 2021 IQVIA Health data, AmBisome® Liposome for Injection, 50mg/vial had annualized sales of approximately US$ 136 million in USA.